Nurix IPO

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels by controlling ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Total Funding to Date$48.38MM
Register for Details

For more details on financing and valuation for Nurix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in